{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:51:46Z","timestamp":1775947906916,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.healun.2025.12.030","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T16:22:11Z","timestamp":1767457331000},"page":"810-819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preventing invasive aspergillosis in lung transplant recipients: A cost-utility analysis"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7495-3398","authenticated-orcid":false,"given":"Roni","family":"Bitterman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5338-8693","authenticated-orcid":false,"given":"Aida","family":"Glembocki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7048-6590","authenticated-orcid":false,"given":"Laura N.","family":"Walti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9216-5229","authenticated-orcid":false,"given":"Shahid","family":"Husain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-7936","authenticated-orcid":false,"given":"Petros","family":"Pechlivanoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2025.12.030_bib1","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13250","article-title":"Incidence and outcomes of invasive fungal infection among solid organ transplant recipients: a population-based cohort study","volume":"22","author":"Hosseini-Moghaddam","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib2","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1086\/651262","article-title":"Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (Transnet)","volume":"50","author":"Pappas","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib3","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.healun.2018.06.008","article-title":"Clinical risk factors for invasive aspergillosis in lung transplant recipients: results of an international cohort study","volume":"37","author":"Aguilar","year":"2018","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.healun.2025.12.030_bib4","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/jof9111079","article-title":"Invasive aspergillosis among lung transplant recipients during time periods with universal and targeted antifungal prophylaxis-a nationwide cohort study","volume":"9","author":"Crone","year":"2023","journal-title":"J Fungi"},{"key":"10.1016\/j.healun.2025.12.030_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1399-3062.2010.00492.x","article-title":"Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients","volume":"12","author":"Neofytos","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10096-007-0376-3","article-title":"Aspergillus infection in lung transplant patients: incidence and prognosis","volume":"26","author":"Iversen","year":"2007","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib7","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/ajt.12691","article-title":"Epidemiology of invasive mold infections in lung transplant recipients","volume":"14","author":"Doligalski","year":"2014","journal-title":"Am J Transpl"},{"key":"10.1016\/j.healun.2025.12.030_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001128","article-title":"Risk of lung allograft dysfunction associated with aspergillus infection","volume":"7","author":"Le Pavec","year":"2021","journal-title":"Transpl Direct"},{"key":"10.1016\/j.healun.2025.12.030_bib9","first-page":"261","article-title":"The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary","volume":"35","author":"Husain","year":"2016"},{"key":"10.1016\/j.healun.2025.12.030_bib10","article-title":"The impact of antifungal prophylaxis in lung transplant recipients","author":"Pennington","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.healun.2025.12.030_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-6143.2010.03375.x","article-title":"Antifungal prophylaxis in lung transplantation-a world-wide survey","volume":"11","author":"Neoh","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.healun.2025.12.030_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/tid.12337","article-title":"Practice variation in Aspergillus prophylaxis and treatment among lung transplant centers: a national survey","volume":"17","author":"He","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib13","article-title":"Isavuconazole is as effective as and better tolerated than Voriconazole for antifungal prophylaxis in lung transplant recipients","author":"Samanta","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib14","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13067","article-title":"Why do lung transplant patients discontinue triazole prophylaxis?","volume":"21","author":"Pennington","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13630","article-title":"Antifungal prophylaxis in lung transplant: a survey of United States\u2019 transplant centers","volume":"33","author":"Pennington","year":"2019","journal-title":"Clin Transpl"},{"key":"10.1016\/j.healun.2025.12.030_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jof7020122","article-title":"Strategies for the prevention of invasive fungal infections after lung transplant","volume":"7","author":"Bitterman","year":"2021","journal-title":"J Fungi"},{"key":"10.1016\/j.healun.2025.12.030_bib17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11908-013-0380-y","article-title":"Anti-aspergillus prophylaxis in lung transplantation: a systematic review and meta-analysis","volume":"15","author":"Bhaskaran","year":"2013","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.healun.2025.12.030_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13333","article-title":"Antifungal prophylaxis in lung transplant recipients: a systematic review and meta-analysis","volume":"22","author":"Pennington","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib19","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib20","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/TP.0b013e31825992f0","article-title":"Emergence of Aspergillus calidoustus infection in the era of posttransplantation azole prophylaxis","volume":"94","author":"Egli","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2025.12.030_bib21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/tri.12679","article-title":"10 years of prophylaxis with nebulized liposomal amphotericin B and the changing epidemiology of Aspergillus spp. infection in lung transplantation","volume":"29","author":"Peghin","year":"2016","journal-title":"Transpl Int"},{"key":"10.1016\/j.healun.2025.12.030_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/tid.12492","article-title":"Epidemiology of invasive respiratory disease caused by emerging non-Aspergillus molds in lung transplant recipients","volume":"18","author":"Peghin","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib23","first-page":"165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Rev Pharm Outcomes Res"},{"key":"10.1016\/j.healun.2025.12.030_bib24","unstructured":"Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies: Canada, 4th edition. 2017. Available at: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/www.cda-amc.ca\/sites\/default\/files\/pdf\/guidelines_for_the_economic_evaluation_of_health_technologies_canada_4th_ed.pdf."},{"key":"10.1016\/j.healun.2025.12.030_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0272989X221103163","article-title":"An introductory tutorial on cohort state-transition models in R using a cost-effectiveness analysis example","volume":"43","author":"Alarid-Escudero","year":"2023","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.healun.2025.12.030_bib26","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1093\/cid\/ciz1113","article-title":"Burden and timeline of infectious diseases in the first year after solid organ transplantation in the swiss transplant cohort study","volume":"71","author":"van Delden","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/0272989X221121747","article-title":"A tutorial on time-dependent cohort state-transition models in R using a cost-effectiveness analysis example","volume":"43","author":"Alarid-Escudero","year":"2023","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.healun.2025.12.030_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40273-015-0337-0","article-title":"Myths and misconceptions of within-cycle correction: a guide for modelers and decision makers","volume":"34","author":"Elbasha","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.healun.2025.12.030_bib29","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1097\/TP.0000000000003187","article-title":"Late onset invasive pulmonary Aspergillosis in lung transplant recipients in the setting of a targeted prophylaxis\/preemptive antifungal therapy strategy","volume":"104","author":"Herrera","year":"2020","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2025.12.030_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(21)00219-1","article-title":"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial","volume":"397","author":"Maertens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.healun.2025.12.030_bib31","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.healun.2025.12.030_bib32","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1600-6143.2012.04042.x","article-title":"Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients","volume":"12","author":"Luong","year":"2012","journal-title":"Am J Transpl"},{"key":"10.1016\/j.healun.2025.12.030_bib33","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/microorganisms10122478","article-title":"Adverse events associated with universal versus targeted antifungal prophylaxis among lung transplant recipients-A Nationwide Cohort Study 2010-2019","volume":"10","author":"Crone","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.healun.2025.12.030_bib34","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.healun.2025.12.030_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13448","article-title":"Evaluation of targeted versus universal prophylaxis for the prevention of invasive fungal infections following lung transplantation","volume":"23","author":"Linder","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1600-6143.2004.00641.x","article-title":"Determinants of health utility in lung and heart-lung transplant recipients","volume":"5","author":"Singer","year":"2005","journal-title":"Am J Transpl"},{"key":"10.1016\/j.healun.2025.12.030_bib37","first-page":"805","article-title":"Economic evaluation of isavuconazole for suspected invasive pulmonary aspergillosis in Canada","volume":"22","author":"Beauchemin","year":"2022","journal-title":"Expert Rev Pharm Outcomes Res"},{"key":"10.1016\/j.healun.2025.12.030_bib38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3111\/13696998.2014.971158","article-title":"Utilities for treatment-related adverse events in type 2 diabetes","volume":"18","author":"Shingler","year":"2015","journal-title":"J Med Econ"},{"key":"10.1016\/j.healun.2025.12.030_bib39","unstructured":"Ontario Drug Benefit (ODB) Formulary. Accessed December 6, 2024. Available at: https:\/\/www.ontario.ca\/document\/ontario-drug-benefit-odb-formulary-comparative-drug-index-cdi-and-monthly-formulary-0."},{"key":"10.1016\/j.healun.2025.12.030_bib40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/SLA.0000000000005887","article-title":"Evaluating the impact of ex vivo lung perfusion on organ transplantation: a retrospective cohort study","volume":"278","author":"Peel","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.healun.2025.12.030_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13148","article-title":"Cost-effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic stem cell transplant","volume":"21","author":"Walker","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib42","unstructured":"Ontario Health Insurance Plan (OHIP). Schedule of Benefits for Laboratory Services. Available at: www.ontario.ca\/files\/2025\u201303\/moh-ohip-schedule-of-benefits-laboratory-services-2025\u201303-03.pdf."},{"key":"10.1016\/j.healun.2025.12.030_bib43","unstructured":"Ontario Health Insurance Plan (OHIP). Schedule of Benefits for Physician Services. Available at: www.ontario.ca\/files\/2025\u201303\/moh-schedule-benefit-2025\u201303-19.pdf."},{"key":"10.1016\/j.healun.2025.12.030_bib44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jval.2020.01.001","article-title":"Value of information analysis for research decisions\u2014an introduction: report 1 of the ISPOR value of information analysis emerging good practices task force","volume":"23","author":"Fenwick","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.healun.2025.12.030_bib45","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s40273-019-00844-y","article-title":"TECH-VER: a verification checklist to reduce errors in models and improve their credibility","volume":"37","author":"B\u00fcy\u00fckkaramikli","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.healun.2025.12.030_bib46","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2165\/11588370-000000000-00000","article-title":"Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence","volume":"29","author":"Pechlivanoglou","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.healun.2025.12.030_bib47","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae537","article-title":"Exhaled breath condensate surveillance for aspergillus in acute leukemia-a pilot trial","volume":"11","author":"Bitterman","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib48","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.healun.2025.12.030_bib49","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/bmt.2010.38","article-title":"Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT","volume":"45","author":"Blennow","year":"2010","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.healun.2025.12.030_bib50","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.healun.2018.02.006","article-title":"A strategy for prevention of fungal infections in lung transplantation: role of bronchoalveolar lavage fluid galactomannan and fungal culture","volume":"37","author":"Husain","year":"2018","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.healun.2025.12.030_bib51","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jamadermatol.2020.1141","article-title":"Voriconazole and the risk of keratinocyte carcinomas among lung transplant recipients in the United States","volume":"156","author":"D\u2019Arcy","year":"2020","journal-title":"JAMA Dermatol"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249825024830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249825024830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:39:33Z","timestamp":1775947173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249825024830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1053249825024830"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2025.12.030","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preventing invasive aspergillosis in lung transplant recipients: A cost-utility analysis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2025.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation.","name":"copyright","label":"Copyright"}]}}